Enhertu recommended for EU approval in HER2+ metastatic solid tumours
Enhertu has been recommended for approval by the CHMP for patients with previously treated HER2-positive metastatic solid tumours.
Published: June 2, 2026
Updated: June 2, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / HER2-positive solid tumours
Asset: Oncology
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Oncology
Indication
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
This approval could enhance AstraZeneca and Daiichi Sankyo's market position in oncology, particularly in the HER2-targeted therapy space.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor the final approval decision from the European Commission and subsequent market access strategies.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.